In 2016, Dr. David Richardson was also using ECP. Today he would most likely recommend the micropulse version of ECP, which is called MP-TSCPC. (Of course, that is determined by a consultation between him and the patient.) Please see this link for his recent comments on MP-TSCPC:
What is Micropulse transscleral cyclophotocoagulation for glaucoma? | Ask FitEyes
In 2016, Dr. David Richardson shared the following comments on ECP (and other options):
Ab-interno canaloplasty is an exciting variation of canaloplasty with great potential. It could be the first Minimally Invasive Glaucoma Surgery (MIGS) that actually works. Quick disclosure: I'm not impressed with the results of the other MIGS procedures currently available in the USA: trabectome, endocyclophotocoagulation, and iStent.
Early results of Ab-interno Canaloplasty (or ABiC) are promising but there are no long-term results available yet as this variation of the procedure is only about a year old (as of 2016).
In 2016, he said: the latest presented-but-not-yet-published data are:
After undergoing ABiC, 32 patients were at the 6 months post op stage and had an average IOP reduction of 38% (a drop of 8.5mmHg) down to 13.3 on 1 medication.
Pretty impressive, but it is a small study with limited follow-up.
I have not, to date, performed ABiC. Why? Because those who travel to see me (and a large percentage of my patients needing glaucoma surgery travel from significant, if not great, distances) expect to have Ab-Externo Canaloplasty due to it's established and impressive track record both in safety and IOP lowering effect. I would, however, consider it in someone who was on anticoagulation (blood thinners) who could not safely be taken off of them as Ab-Externo Canaloplasty is exceedingly challenging (and not always possible) in those who are actively anticoagulated.
David Richardson, MD